"Buzz on the Street" Show: Smart Decision (OTC: SDEC) Signs Letter of Intent with LBC Bioscience | Financial Buzz

“Buzz on the Street” Show: Smart Decision (OTC: SDEC) Signs Letter of Intent with LBC Bioscience

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Smart Decision, Inc. Signs Letter of Intent (LOI) With LBC Bioscience Inc. for CBDSMARTDECISION.COM Upcoming CBD Algorithm.”

Smart Decision, Inc. (OTC: SDEC), a next-generation consumer-based LED & CBD algorithm innovator, is pleased to announce that it has signed a Letter of Intent (LOI) with LBC Bioscience Inc., a visionary in the CBD space.

Smart Decision Inc. has researched and is developing algorithms for the consumer and business LED Lighting and CBD markets.  With their patent-pending “Smart Decision” algorithms, the confusion of selecting the right product(s), whether for LED or CBD, will be significantly reduced. Ultimately, Smart Decision Inc. believes that selecting the right product the first time, dramatically cuts down on product returns and creates of positive purchasing experience for the consumer.

Anxiety disorders are one of the most common mental illnesses in the U.S., affecting nearly 40 million adults, according to the Anxiety and Depression Association of America. Anxiety disorders are highly treatable, yet only 36.9% of those suffering actually receive treatment. Generally, people with anxiety disorders are three to five times more likely to visit a doctor and six times more likely to be hospitalized for psychiatric disorders than those who do not suffer from anxiety disorders. Furthermore, the discrepancy between people who receive treatment and those who seek medical attention is alarming. Additionally, the cost of treatment and medical visits can become quite high, especially for people who lack access to adequate healthcare coverage. Typical low-cost treatments such as cognitive-behavioral therapy can cost roughly USD 100.00 or more per hour. Plus, some healthcare insurers do not provide coverage for certain medications, making it increasingly difficult for people suffering from anxiety to manage their conditions. Consequently, many people have decided to turn to CBD or cannabidiol to suppress their anxiety disorders. CBD is a derivative of cannabis, but unlike its marijuana counterpart, the compound does not cause psychotropic effects on the consumer. Instead, CBD offers a relaxing effect in addition to a handful of therapeutic benefits. As such, it is now commonly being used for health and wellness purposes, however, researchers have determined that CBD can also be used to alleviate more serious medical conditions. Notably, medical practitioners have prescribed CBD to patients to better manage symptoms associated with severe conditions such as cancer, chronic pain, Alzheimer’s, Parkinson’s and epilepsy. In particular, the use of CBD to relieve anxiety has become increasingly popular due to the sheer number of people suffering from anxiety disorders. And as a result, the global cannabidiol market is expected to increase from USD 303 Million in 2018 to USD 2.28 Billion by 2025 while registering a CAGR of 33.5%, according to data compiled by QY Research. 

The human body has many different types of receptors that are attached to cells. CBD is thought to interact with CB1 and CB2 receptors, which are most commonly found throughout the central nervous system and the peripheral nervous system, respectively. Although the exact method of how CBD affects CB1 receptors in the brain isn’t fully understood yet, researchers believe it may alter serotonin signals, according to Healthline. Serotonin is a neurotransmitter that plays a vital role in mental health as low-levels of serotonin are commonly associated with people who suffer from depression. In some cases, not having enough serotonin can also cause anxiety. For generalized anxiety disorder, the National Institute on Drug Abuse noted that CBD has been shown to reduce anxiety in animals such as rats. Moreover, according to other studies, test subjects were observed having lower behavioral signs of anxiety. Additionally, their physiological symptoms of anxiety, such as increased heart rate, also improved. Furthermore, researchers have also discovered that CBD can be used to treat other forms of anxiety such as social anxiety disorder and post-traumatic stress disorder. In 2011, a study concluded that people suffering from social anxiety disorder experienced reduced anxiety levels. On the other hand, multiple recent studies have shown that CBD helped manage PTSD symptoms such as nightmares and the replaying of negative memories. However, despite ongoing advancements within the CBD marketspace, researchers have noted that there isn’t enough evidence gathered from clinical trials of CBD to officially approve it as a medication for anxiety disorders. Regardless, consumers can simply purchase CBD-based products such as tinctures, beverages, topicals, and even flower at retailers and even online e-commerce platforms. “Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of CBD exist in the psychiatric literature,” according to an abstract of a study published in the U.S. National Library of Medicine by researchers Scott Shannon, MD, Nicole Lewis, ND, Heather Lee, PA-C, and Shannon Hughes, PhD. “Cannabidiol may hold benefit for anxiety-related disorders.”

For more information, please visit: Smart Decision Inc.

About Behind the Buzz: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

2 Comments
  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For smart decision inc., financial and corporate news dissemination, FinancialBuzz.com has been compensated four thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.